Anagliptin vs Prusogliptin

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Type 2 Diabetes

Shared mechanism: DPP-4 · full Type 2 Diabetes pipeline

Anagliptin · Suiny

Marketed by Sanwa Kagaku Kenkyusho and partners

Phase 3 in Type 2 Diabetessmall molecule
Partial signal

NCT01529541 · Phase 3 · completed

The study randomly assigned an estimated 200 participants and used triple masking with sitagliptin as an active comparator. Its primary endpoint was the change in HbA1c, a surrogate measure, and no primary-outcome result is available to show whether the comparison was favorable.

Next expected readout: March 2027 · NCT07442006 (registry estimate)

Reported efficacy

The Change in HbA1c from baseline to week24 (0wk, 8wk, 16wk, 24wk): HbA1c change from baseline to Week 24: anagliptin 100 mg -0.50±0.45%, anagliptin 200 mg -0.51±0.55%, placebo +0.23±0.62% (n=37/33/39, baseline HbA1c 7.14±0.69%); described as significant reductions vs placebo. (met)

Result source: NCT01529528

Prusogliptin · Shanzeping

Marketed by CSPC Pharmaceutical Group and partners

Phase 3 in Type 2 Diabetessmall molecule
Reliable signal

NCT04161430 · Phase 3 · completed

In this randomized, quadruple-blind, placebo- and active-controlled Phase 3 trial, 766 patients with type 2 diabetes were randomized to DBPR108, sitagliptin, or placebo. DBPR108 reduced HbA1c significantly more than placebo at 24 weeks, with a treatment difference whose confidence interval excluded no effect.

Reported efficacy

Change from baseline in HbA1c (%) compared to placebo comparator at week 24 (Baseline, week 24): HbA1c change from baseline at week 24: -0.63% (DBPR108) vs -0.02% (placebo); treatment difference -0.61 percentage points (95% CI -0.77% to -0.44%). DBPR108 was superior to placebo. (met)

Result source: NCT04161430

Results for Type 2 Diabetes

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointAnagliptinPrusogliptin
HbA1c, change-0.5% vs 0.2%a−0.7 vs placeboanagliptin 200 mg · wk 24NCT01529528
2 other results
  • -0.5% vs 0.2% anagliptin 100 mg · wk 24 · Phase 3 · primary NCT01529528
  • -0.8% vs -0.8% wk 24 · Phase 3 · primary NCT01529541
-0.6% vs -0.0%a−0.6 vs placebowk 24NCT04161430
1 other result
Body weight, change (kg)—Not posted · NCT01529528—Not posted · NCT04218734
HbA1c below 7%—Not posted · NCT01529528—Not posted · NCT04218734
Fasting plasma glucose, change—Not posted · NCT01529528—Not posted · NCT04218734
3-point MACE (% with event)—Not posted · NCT01529528—Not posted · NCT04218734

HbA1c, change

Anagliptin
-0.5% vs 0.2%a−0.7 vs placeboanagliptin 200 mg · wk 24NCT01529528
2 other results
  • -0.5% vs 0.2% anagliptin 100 mg · wk 24 · Phase 3 · primary NCT01529528
  • -0.8% vs -0.8% wk 24 · Phase 3 · primary NCT01529541
Prusogliptin
-0.6% vs -0.0%a−0.6 vs placebowk 24NCT04161430
1 other result

Body weight, change (kg)

Anagliptin
—Not posted · NCT01529528
Prusogliptin
—Not posted · NCT04218734

HbA1c below 7%

Anagliptin
—Not posted · NCT01529528
Prusogliptin
—Not posted · NCT04218734

Fasting plasma glucose, change

Anagliptin
—Not posted · NCT01529528
Prusogliptin
—Not posted · NCT04218734

3-point MACE (% with event)

Anagliptin
—Not posted · NCT01529528
Prusogliptin
—Not posted · NCT04218734
  1. a From a reviewed publication or company release; CT.gov has no posted result for this endpoint.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Anagliptin: 0 of 4 rows · Prusogliptin: 3 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricAnagliptinPrusogliptin
Dropout rate—
0%600 mga
NCT01650324 · Phase 1 · registry result, not featured evidence
show 3 more results
0%300 mg
NCT01650324 · Phase 1 · registry result, not featured evidence
0%100 mg
NCT01650324 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT01650324 · Phase 1 · registry result, not featured evidence
Discontinued due to AEs—
—600 mga
NCT01650324 · Phase 1 · registry result, not featured evidence
show 3 more results
—300 mg
NCT01650324 · Phase 1 · registry result, not featured evidence
—100 mg
NCT01650324 · Phase 1 · registry result, not featured evidence
—25 mg
NCT01650324 · Phase 1 · registry result, not featured evidence
Serious AEs—
0%600 mga
NCT01650324 · Phase 1 · registry result, not featured evidence
show 3 more results
0%300 mg
NCT01650324 · Phase 1 · registry result, not featured evidence
0%100 mg
NCT01650324 · Phase 1 · registry result, not featured evidence
0%25 mg
NCT01650324 · Phase 1 · registry result, not featured evidence
Most frequent reported AEs—
600 mga
haematuria 16.7% (placebo 0%)
infection 16.7% (placebo 0%)
ligament sprain 16.7% (placebo 0%)
NCT01650324 · Phase 1 · registry result, not featured evidence
show 3 more results
300 mg
platelet count decreased 16.7% (placebo 0%)
haematuria 0% (placebo 0%)
infection 0% (placebo 0%)
NCT01650324 · Phase 1 · registry result, not featured evidence
100 mg
haematuria 0% (placebo 0%)
infection 0% (placebo 0%)
ligament sprain 0% (placebo 0%)
NCT01650324 · Phase 1 · registry result, not featured evidence
25 mg
haematuria 0% (placebo 0%)
infection 0% (placebo 0%)
ligament sprain 0% (placebo 0%)
NCT01650324 · Phase 1 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Anagliptin's landscape · Prusogliptin's landscape